Pharmaceutics (Jan 2023)

Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses

  • Michael Donkor,
  • Jamie Choe,
  • Danielle Marie Reid,
  • Byron Quinn,
  • Mark Pulse,
  • Amalendu Ranjan,
  • Pankaj Chaudhary,
  • Harlan P. Jones

DOI
https://doi.org/10.3390/pharmaceutics15020445
Journal volume & issue
Vol. 15, no. 2
p. 445

Abstract

Read online

Lung metastasis is a leading cause of cancer-related deaths. Here, we show that intranasal delivery of our engineered CpG-coated tumor antigen (Tag)-encapsulated nanoparticles (NPs)—nasal nano-vaccine—significantly reduced lung colonization by intravenous challenge of an extra-pulmonary tumor. Protection against tumor-cell lung colonization was linked to the induction of localized mucosal-associated effector and resident memory T cells as well as increased bronchiolar alveolar lavage-fluid IgA and serum IgG antibody responses. The nasal nano-vaccine-induced T-cell-mediated antitumor mucosal immune response was shown to increase tumor-specific production of IFN-γ and granzyme B by lung-derived CD8+ T cells. These findings demonstrate that our engineered nasal nano-vaccine has the potential to be used as a prophylactic approach prior to the seeding of tumors in the lungs, and thereby prevent overt lung metastases from existing extra pulmonary tumors.

Keywords